-
Megan M. Dupuis, MD, shares the complex journey she traveled during medical training and how it brought her to the academic setting. @MissMeganEl @VUMChealth #oncology https://t.co/1Cfbl8phdK
— OncLive.com (@OncLive) June 18, 2023 -
🚨That also doesn't factor in that the patients directed to adjuvant chemo almost certainly had higher risk disease, while those who didn't were enriched for more favorable disease features.
— H. Jack West, MD (@JackWestMD) June 18, 2023
Know that if you don't recommend adjuvant chemo, you're undertreating. https://t.co/73QGsmEhzd -
The phase 1 PLAT-08 trial investigating SC-DARIC33 in pediatric and young-adult patients with relapsed/refractory CD33-positive acute myeloid leukemia has been paused following the report of a grade 5 serious adverse effect. #leusm #oncology https://t.co/rZlPYGHUA2 pic.twitter.com/SbBxUDC0YP
— OncLive.com (@OncLive) June 18, 2023 -
The first-line combination of lenvatinib and pembrolizumab elicited durable responses with a manageable safety profile in patients with non–clear cell RCC, according to findings from the phase 2 KEYNOTE-B61 trial. @MSKCancerCenter #kcsm https://t.co/IMtagssLqH pic.twitter.com/flbFFz6uhd
— OncLive.com (@OncLive) June 18, 2023 -
1-stage synovectomy was associated with a similar range of motion & fewer complications compared w/ 2-stage synovectomy in patients w/ D-TGCT of the knee, & the 1-stage procedure should be considered when feasible @RLRandallMD @UCDavisHealth #oncology https://t.co/Hc9tkxscUB pic.twitter.com/EV0g89pDuE
— OncLive.com (@OncLive) June 18, 2023
Oncology